In the field of medical and scientific research, radionuclides are used to investigate various physiological and pathological processes. PRISMAP - the European medical radionuclide programme was created to bring together production facilities including intense neutron sources, an isotope mass separation facility, high-power accelerators, biomedical research institutes, and hospitals to support medical research. The aim of this article is to introduce readers with the current status of innovative radionuclides in Europe. A survey was created targeting the latest trends mainly focused on the demand, the production and the distribution of non-routinely used medical radionuclides for use in research, and for pre-clinical and clinical trials. This survey has been disseminated through the PRISMAP community. 16 of 104 respondents were working in the field of radionuclide production. The data found common aspects from all producer-facility respondents: the biggest challenge for the producers is the availability of target materials, which goes hand-in-hand with their purity/enrichment grade. The results show that there are sufficient national or international distribution routes and methods established, although having reported challenges due to legislation constraints, especially for novel radionuclides. Thanks to a questionnaire distributed by the PRISMAP consortium, the current status in radionuclides production was identified. Understanding the current status of radionuclide production is essential for assessing the continent’s capabilities and addressing the burgeoning demands for cutting-edge medical radionuclides.
Sterilization is essential for hydrogel-based biomaterials, but it can also determine the final material state. This study used ionically crosslinked alginate hydrogels as a model system to evaluate sterilization as a coupled process linking microbial inactivation and hydrogel structural reorganization. Steam sterilization, gamma irradiation, ethylene oxide (EtO), ultraviolet (UV) irradiation, and high hydrostatic pressure (HHP) treatment were assessed within the same model system. Microbiological effectiveness was assessed using surface- and matrix-associated contamination models, while structural responses were evaluated by rheology, dimensional changes, and swelling behavior. Steam sterilization, gamma irradiation, EtO, and selected HHP conditions resulted in no detectable microbial growth under the tested conditions, whereas UV irradiation was insufficient to eliminate detectable growth from matrix-associated contamination. However, microbiologically effective treatments produced distinct material profiles. Steam generated a compact and stiff hydrogel state, gamma irradiation produced softened but deformation-tolerant networks, EtO caused pronounced dimensional alteration and high deformability, and HHP produced softened, water-accessible hydrogels with parameter-dependent responses. These findings show that sterilization method selection should integrate microbial inactivation with the final structural state required for application-specific hydrogel performance.
30 April 2026 in EJNMMI Radiopharmacy and Chemistry
Scandium radionuclides are emerging theranostic radionuclides that offer matched diagnostic and therapeutic emissions for targeted applications in nuclear
Background and Objectives: Diabetes mellitus (Type 2 diabetes) is a significant and rapidly growing global healthcare challenge and a leading cause of severe complications, including cardiovascular disease (CVD), chronic kidney disease and other conditions. In Latvia more than 103 000 individuals have been registered in the Latvian Diabetes Patient Register, of whom over 90% had type 2 diabetes. Since early diagnosis can reduce complication risk, considerable effort has been devoted to the development of numerous CVD risk prediction tools using traditional statistics as well as data science-based methods. This article augments these efforts with predictive models built specifically for Latvia’s diabetes patient population. Materials and Methods: Models used anonymized diabetes patient data stored at Latvia’s Center for Disease Prevention and Control containing routinely collected information on patients’ utilization of publicly funded healthcare services. No clinical data were included. In keeping with best practices in model development, 96 302 qualifying available patient records were randomly partitioned into a 70% training data portion and 30% for out-of-sample validation. We tested three modeling methodologies – logistic regression, Random Forests, and XGBoost. Results: The binary dependent variable was defined as the occurrence of an ischemic heart disease hospitalization during 2023 or 2024. The predictor variables were limited to data from the prior two year period, 2021-2022. The three model types all produced similar fit to the data – area under the Receiver Operating Curve (ROC) of 0.70-0.71 in the validation data, which is comparable to results obtained in other studies, including SCORE2. Prediction reliability, as measured by the Brier Score, was 0.11. Conclusions: We find ischemic heart disease hospitalization risk prediction models based on routinely collected Latvian health care utilization data to be feasible. Such a model could be applied to identify diabetes patients with an elevated (30%-40%) risk of experiencing an ischemic heart disease-related hospitalization over the next two years. While the actual size of Latvia’s diabetes patient population in the near future is not precisely known, we estimate that this highest risk decile may contain a group of 8 000 – 10 000 diabetes patients. We suggest future prospective studies to evaluate whether integrating the model into primary care can lead to earlier interventions and a reduction in preventable ischemic heart disease hospitalizations.
Background and Objectives: Diabetes mellitus (Type 2 diabetes) is a significant and rapidly growing global healthcare challenge and a leading cause of severe complications, including cardiovascular disease (CVD), chronic kidney disease and other conditions. In Latvia, more than 103 000 individuals have been registered in the Latvian Diabetes Patient Register, of whom over 90% have type 2 diabetes. Since early diagnosis can reduce complication risk, considerable effort has been devoted to the development of numerous CVD risk prediction tools using traditional statistics as well as data science-based methods. This article augments these efforts with predictive models built specifically for Latvia’s diabetes patient population. Materials and Methods: Models used anonymized diabetes patient data stored at Latvia’s Center for Disease Prevention and Control, containing routinely collected information on patients’ utilization of publicly funded healthcare services. No clinical data were included. In keeping with best practices in model development, 96,302 qualifying available patient records were randomly partitioned into a 70% training data portion and 30% for out-of-sample validation. We tested three modeling methodologies—logistic regression, Random Forests, and XGBoost. Results: The binary dependent variable was defined as the occurrence of an ischemic heart disease hospitalization during 2023 or 2024. The predictor variables were limited to data from the prior two-year period, 2021–2022. The three model types all produced similar fit to the data—area under the Receiver Operating Curve (ROC) of 0.69–0.71 in the validation data, which is comparable to results obtained in other studies, including SCORE2. Prediction reliability, as measured by the Brier Score, was 0.11. Conclusions: We find ischemic heart disease hospitalization risk prediction models based on routinely collected Latvian health care utilization data to be feasible. Such a model could be applied to identify diabetes patients with an elevated (30–40%) risk of experiencing an ischemic heart disease-related hospitalization over the next two years. In a retrospective validation cohort, the highest risk decile had an observed two-year hospitalization rate above 30%. An illustrative projection of a similarly sized decile is about 8000–10,000 patients, but this estimate is exploratory. The model is not ready for clinical implementation; prospective studies are required to test calibration, clinical utility, and benefit. We suggest future research to evaluate whether integrating the model into primary care can lead to earlier interventions and a reduction in preventable ischemic heart disease hospitalizations.